530 related articles for article (PubMed ID: 29450785)
1. The role of the alternative pathway of complement activation in glomerular diseases.
Łukawska E; Polcyn-Adamczak M; Niemir ZI
Clin Exp Med; 2018 Aug; 18(3):297-318. PubMed ID: 29450785
[TBL] [Abstract][Full Text] [Related]
2. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies.
Servais A; Noël LH; Roumenina LT; Le Quintrec M; Ngo S; Dragon-Durey MA; Macher MA; Zuber J; Karras A; Provot F; Moulin B; Grünfeld JP; Niaudet P; Lesavre P; Frémeaux-Bacchi V
Kidney Int; 2012 Aug; 82(4):454-64. PubMed ID: 22456601
[TBL] [Abstract][Full Text] [Related]
3. Molecules Great and Small: The Complement System.
Mathern DR; Heeger PS
Clin J Am Soc Nephrol; 2015 Sep; 10(9):1636-50. PubMed ID: 25568220
[TBL] [Abstract][Full Text] [Related]
4. The role of complement in C3 glomerulopathy.
Zipfel PF; Skerka C; Chen Q; Wiech T; Goodship T; Johnson S; Fremeaux-Bacchi V; Nester C; de Córdoba SR; Noris M; Pickering M; Smith R
Mol Immunol; 2015 Sep; 67(1):21-30. PubMed ID: 25929733
[TBL] [Abstract][Full Text] [Related]
5. Glomerular basement membrane heparan sulfate in health and disease: A regulator of local complement activation.
Borza DB
Matrix Biol; 2017 Jan; 57-58():299-310. PubMed ID: 27609404
[TBL] [Abstract][Full Text] [Related]
6. Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement.
Sethi S; Fervenza FC; Zhang Y; Nasr SH; Leung N; Vrana J; Cramer C; Nester CM; Smith RJ
Clin J Am Soc Nephrol; 2011 May; 6(5):1009-17. PubMed ID: 21415311
[TBL] [Abstract][Full Text] [Related]
7. C3 Glomerulonephritis With Multiple Mutations in Complement Factor H.
Dalili N; Behnam B; Vali F; Parvin M; Torbati P; Rasaii N; Samadian F; Ahmadpoor P
Iran J Kidney Dis; 2018 Nov; 12(6):376-381. PubMed ID: 30595568
[TBL] [Abstract][Full Text] [Related]
8. [Complement system regulation and C3 glomerulopathy].
Xiao HJ; He RJ
Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Apr; 45(2):323-6. PubMed ID: 23591359
[TBL] [Abstract][Full Text] [Related]
9. C3 glomerulopathy: what's in a name?
D'Agati VD; Bomback AS
Kidney Int; 2012 Aug; 82(4):379-81. PubMed ID: 22846813
[TBL] [Abstract][Full Text] [Related]
10. The susceptibility of the kidney to alternative pathway activation-A hypothesis.
Thurman JM; Harrison RA
Immunol Rev; 2023 Jan; 313(1):327-338. PubMed ID: 36369971
[TBL] [Abstract][Full Text] [Related]
11. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up.
Sethi S; Fervenza FC; Zhang Y; Zand L; Vrana JA; Nasr SH; Theis JD; Dogan A; Smith RJ
Kidney Int; 2012 Aug; 82(4):465-73. PubMed ID: 22673887
[TBL] [Abstract][Full Text] [Related]
12. Effects of complement factor D deficiency on the renal disease of MRL/lpr mice.
Elliott MK; Jarmi T; Ruiz P; Xu Y; Holers VM; Gilkeson GS
Kidney Int; 2004 Jan; 65(1):129-38. PubMed ID: 14675043
[TBL] [Abstract][Full Text] [Related]
13. C4d as a Diagnostic Tool in Proliferative GN.
Sethi S; Nasr SH; De Vriese AS; Fervenza FC
J Am Soc Nephrol; 2015 Nov; 26(11):2852-9. PubMed ID: 25991041
[TBL] [Abstract][Full Text] [Related]
14. Case report: lupus nephritis with autoantibodies to complement alternative pathway proteins and C3 gene mutation.
Nozal P; Garrido S; Martínez-Ara J; Picazo ML; Yébenes L; Álvarez-Doforno R; Pinto S; de Córdoba SR; López-Trascasa M
BMC Nephrol; 2015 Mar; 16():40. PubMed ID: 25886501
[TBL] [Abstract][Full Text] [Related]
15. Serum properdin consumption as a biomarker of C5 convertase dysregulation in C3 glomerulopathy.
Corvillo F; Bravo García-Morato M; Nozal P; Garrido S; Tortajada A; Rodríguez de Córdoba S; López-Trascasa M
Clin Exp Immunol; 2016 Apr; 184(1):118-25. PubMed ID: 26660535
[TBL] [Abstract][Full Text] [Related]
16. Distinct roles for the complement regulators factor H and Crry in protection of the kidney from injury.
Laskowski J; Renner B; Le Quintrec M; Panzer S; Hannan JP; Ljubanovic D; Ruseva MM; Borza DB; Antonioli AH; Pickering MC; Holers VM; Thurman JM
Kidney Int; 2016 Jul; 90(1):109-22. PubMed ID: 27165610
[TBL] [Abstract][Full Text] [Related]
17. The significance of in vitro activation of guinea pig complement in glomeruli of human renal biopsy materials from varied subtypes of glomerulonephritis.
Masugi Y; Kogoshi T; Ishizaki M
Acta Pathol Jpn; 1980 Nov; 30(6):995-1007. PubMed ID: 7446122
[TBL] [Abstract][Full Text] [Related]
18. Complement inhibition in C3 glomerulopathy.
Nester CM; Smith RJ
Semin Immunol; 2016 Jun; 28(3):241-9. PubMed ID: 27402056
[TBL] [Abstract][Full Text] [Related]
19. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome.
Servais A; Frémeaux-Bacchi V; Lequintrec M; Salomon R; Blouin J; Knebelmann B; Grünfeld JP; Lesavre P; Noël LH; Fakhouri F
J Med Genet; 2007 Mar; 44(3):193-9. PubMed ID: 17018561
[TBL] [Abstract][Full Text] [Related]
20. Clinico-Pathogenic Similarities and Differences between Infection-Related Glomerulonephritis and C3 Glomerulopathy.
Wada Y; Kamata M; Miyasaka R; Abe T; Kawamura S; Takeuchi K; Aoyama T; Oda T; Takeuchi Y
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
